Navigation Links
Researchers close in on new melanoma gene
Date:5/19/2008

Phoenix, Arizona and Queensland, Australia It has long been known that prolonged exposure to the suns harmful UV rays can lead to Melanoma, the deadliest form of skin cancer. An unanswered question, however, is why some people are more likely to develop melanoma than others. Despite years of research and clinical development, melanoma incidences continue to rise around the world. According to the National Cancer Institute, the percentage of people in the United States who develop melanoma each year has more than doubled in the past 30 years.

Results published today from a study led by researchers from The Translational Genomic Research Institute (TGen) in Phoenix, Arizona and The Queensland Institute of Medical Research (QIMR), Queensland, Australia, however, may yet change these statistics. The team is close to discovering a new gene that could help explain variation in melanoma risk.

In a report appearing in an Advance Online Publication (AOP) of the journal Nature Genetics, the researchers and their colleagues identify a region on chromosome 20 (20q11.22) that influences a persons risk of developing melanoma.

According to Dr Kevin Brown, TGen Investigator and the papers co-first author, compared to other genetic research focusing on familial (or inherited) cases of melanoma, this finding holds implications for the general population

Were closing in on genetic variants which cause 16 percent of the population to be at nearly double the increased risk of developing the disease. In public health terms, this finding is highly significant, Dr. Brown said.

The researchers narrowed the gene location through a genome-wide association study a first in melanoma research. Genome-wide studies involve rapidly scanning DNA of many people to find genetic variations associated with a particular disease. After identifying new genetic associations, researchers can use the information to develop better strategies to detect, treat and prevent the disease.

The aim of our work is to identify and understand the genetic factors influencing melanoma so we can better predict risk estimates, said QIMRs Dr. Stuart MacGregor, co-first author on the study. This in turn, means people will be better informed and can take the right precautions to avoid developing this increasingly common cancer.

How The Study Works A genome-wide association study involves scanning the DNA from two sets of individuals: those with a particular disease (cases) and those of similar individuals without the disease (controls). The DNA of each sample then undergoes examination for strategically selected markers of genetic variation, called single nucleotide polymorphisms, or SNPs. If certain genetic variations are found to be significantly more frequent in people with the disease compared to people without disease, those variations are said to be "associated" with the disease. The associated genetic variations can serve as roadmaps to the region of the human genome where the disease-causing gene resides.

The study whose data collection began 20 years ago involved more than 4,000 Australian samples (2,019 cases and 2,105 controls) and was a joint project between Australian, American and European research groups.


'/>"/>

Contact: Galen Perry
gperry@tgen.org
602-343-8423
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Traditional herbal medicine kills pancreatic cancer cells, Jefferson researchers report
2. Researchers develop first transgenic monkey model of Huntingtons disease
3. Researchers expand natural killer cells in cord blood to fight leukemia
4. Medical College of Wisconsin researchers identify proteins that help develop mammalian hearts
5. Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers
6. UCSD researchers show link between vitamin D status, breast cancer
7. Researchers find first conclusive evidence of Alzheimers-like brain tangles in nonhuman primates
8. Vancouver researchers discover missing link between TB bacteria and humans
9. 1 of the best researchers in general practice
10. Researchers fine-tune clot-busting treatment for bleeding in brain
11. OHSU Cancer Institute researchers pinpoint how smoking causes cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: